Radioimmunotherapy (RIT) is a targeted cancer treatment that combines the specificity of monoclonal antibodies with the cell-killing power of radiation. Monoclonal antibodies are designed to recognize and bind to specific antigens on the surface of cancer cells, allowing the attached radioactive isotopes to deliver a precise dose of radiation directly to the tumor while minimizing damage to surrounding healthy tissue.